Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study

Stine K. Christensen, Mette L. Winther, Ida J. Laursen,Freja S. Madsen,Carsten Brink, Thomas H. Brix,Eva Ellebaek,Inge Marie Svane, Frederikke S. Hansen,Charlotte Haslund,Olivia K. Laursen,Henrik Schmidt, Ida D. Larsen,Lars Bastholt,Christina H. Ruhlmann

Supportive Care in Cancer(2024)

Cited 0|Views6
No score
Abstract
Immune-related thyroid adverse events (irTAEs) occur frequently following immune checkpoint inhibitor (ICI) therapy. The purpose of this study is to provide knowledge about the incidence, clinical timeline characteristics, associated factors of irTAEs, and potential impact on treatment efficacy in patients with melanoma receiving adjuvant ICI therapy. A national multicenter retrospective cohort study of patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors between November 2018 and December 2020. Data were extracted from the Danish Metastatic Melanoma Database. The irTAEs were defined as two consecutive abnormal TSH values and subdivided into transient or persistent. Of 454 patients, 99 developed an irTAE (21.8
More
Translated text
Key words
Adjuvant,Immune-related adverse events,Immune checkpoint inhibitors,Immune-related thyroiditis,Melanoma,PD-1 inhibitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined